Logo Image

Emily Curran, MD

Articles by Emily Curran, MD

Shifting Goals of Therapy in AYA ALL: From Transplant to Long-Term Remission with Pediatric-Inspired Regimens and Immunotherapy

ByEmily Curran, MD ,Lewis B. Silverman, MD

Dr. Silverman asks Dr. Curran to address how frontline therapy goals have evolved for young adults with ALL in the era of pediatric-inspired regimens (PIRs). Dr. Curran describes a significant paradigm shift: the historical standard in adult oncology held that young, fit patients should achieve remission as a bridge to allogeneic stem cell transplant (allo-SCT), which was considered to offer the best chance of long-term cure. Data supporting PIRs in AYA ALL have fundamentally changed this calculus.

The Case for Pediatric-Inspired Regimens in AYA ALL: Real-World Evidence and Barriers to Adoption

ByEmily Curran, MD ,Lewis B. Silverman, MD

Dr. Lewis Silverman introduces the program on pediatric-inspired asparaginase-based regimens in adolescent and young adult (AYA) ALL, joined by Dr. Emily Curran. The discussion focuses on the 2026 real-world analysis by Freyer and colleagues, which demonstrated significantly higher overall survival in AYAs with ALL treated with guideline-concordant pediatric-inspired regimens compared to adult-inspired regimens. Dr. Curran notes that no randomized trial comparing pediatric-inspired versus adult regimens in the AYA population has been completed to date; the accumulating retrospective and prospective data nonetheless strongly favor pediatric-inspired regimens over historical adult controls.

Latest Updated Articles